Adalvo is pleased to announce the signing of two new strategic distribution partnerships with Blanver, a prominent Brazilian pharmaceutical company, for two technically differentiated, value-add oncology products.
These agreements further strengthen Adalvo's growing presence in Latin America and underline the company's continued commitment to expanding access to high-quality, complex medicines through best-in-class commercial partners.
Each product represents a significant addition to Adalvo's oncology portfolio. Both are value-add medicines and reflect the company's strategic focus on developing and commercialising technically differentiated products that address unmet patient needs across key global markets.
Anil Okay, CEO of Adalvo, commented: "We are delighted to welcome Blanver as a strategic partner. This agreement is a strong demonstration of Adalvo's ability to identify and commercialise high-value oncology assets through trusted partners with deep local expertise. Together, we are well-positioned to make a meaningful difference for patients who need access to innovative treatment options."
Sérgio Frangioni, CEO of Blanver, commented:
“We are strongly committed to expanding strategic partnerships that help bring modern, safe, and effective therapies to Brazilian patients, contributing to better health and quality of life. I am also confident that our partnership with Adalvo will create meaningful value for both companies.”
This partnership is a further testament to Adalvo's 'Always on Target' philosophy — combining a robust, differentiated product pipeline with an extensive global partner network to deliver value to partners and patients alike.
About Adalvo
Adalvo is Europe's fastest-growing B2B pharmaceutical company, providing 170+ partners with end-to-end capabilities spanning product conception to commercialization across 140+ countries. Headquartered in Malta with operations in 20+ countries, Adalvo's high-value portfolio includes over 30 differentiated technologies and a pipeline of ~60 projects due for market entry before 2030.
About Blanver
Blanver is a Brazilian pharmaceutical company with more than 40 years of experience, specialising in the development, manufacturing and commercialisation of active pharmaceutical ingredients and medicines. The company has established capabilities across HIV, hepatitis and osteoporosis, as well as a growing strategic focus on oncology, haematology and rare diseases. Blanver is dedicated to expanding patient access to high-quality, innovative treatments across Brazil and Latin America.